Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
Arcus Biosciences, Inc. (RCUS)
Last arcus biosciences, inc. earnings: 3/5 04:10 pm
Check Earnings Report
Company Research
Source: Business Wire
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a potential best-in-class HIF-2a inhibitor with robust single-agent activity, and multiple data readouts are expected in 2026Arcus’s early development efforts will focus on five programs targeting inflammatory and autoimmune (I&I) diseases; a small molecule targeting MRGPRX2 is expected to enter the clinic in 2026With approximately $1B of cash and investmentsi, Arcus expects to be able to fund its planned operations until at least the second half of 2028 HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study,
Show less
Read more
Impact Snapshot
Event Time:
RCUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCUS alerts
High impacting Arcus Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RCUS
News
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next [Yahoo! Finance]Yahoo! Finance
- Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RCUS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- Arcus Biosciences (NYSE:RCUS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Arcus Biosciences (NYSE:RCUS) was given a new $30.00 price target on by analysts at Truist Financial Corporation.MarketBeat
RCUS
Earnings
- 8/6/25 - Beat
RCUS
Sec Filings
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- 12/15/25 - Form 144
- RCUS's page on the SEC website